The approval of IL-17 and IL-12/23 inhibitors has revolutionized treatment of moderate-to-severe plaque psoriasis in adults and most compounds have recently been approved for use in children aged 6 years and older (9). The gene discussed is IL17A; the disease is psoriasis vulgaris.